Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Janux Therapeutics Inc shares valued at $109,929 were sold by Meyer Andrew Hollman on Dec 01 ’25. At $32.98 per share, Meyer Andrew Hollman sold 3,333 shares. The insider’s holdings dropped to 84,974 shares worth approximately $1.39 million following the completion of this transaction.
Also, BYRON C ROBINSON purchased 63,125 shares, netting a total of over 1,033,743 in proceeds.
Before that, ANDREW MEYER had added 3,333 shares to its account. In a trade valued at $113,622, the Officer bought Janux Therapeutics Inc shares for $34.09 each.
As published in their initiating research note from Wolfe Research on November 18, 2025, Janux Therapeutics Inc [JANX] has been a Peer perform. Analysts at Barclays started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid September. As of September 10, 2025, Truist has initiated its “Buy” rating for JANX. Earlier on September 10, 2025, Stifel initiated its rating. Their recommendation was “a Buy” for JANX stock.
Analyzing JANX Stock Performance
On last trading session, Janux Therapeutics Inc [NASDAQ: JANX] plunged -4.15% to $16.4. The stock’s lowest price that day was $16.3, but it reached a high of $17.2199 in the same session. During the last five days, there has been a drop of approximately -52.72%. Over the course of the year, Janux Therapeutics Inc shares have dropped approximately -59.18%. Shares of the company reached a 52-week high of $61.59 on 01/07/25 and a 52-week low of $15.51 on 12/03/25.
Support And Resistance Levels for Janux Therapeutics Inc (JANX)
According to the 24-hour chart, there is a support level at 16.06, which, if violated, would cause prices to drop to 15.72. In the upper region, resistance lies at 16.98. The next price resistance is at 17.56. RSI (Relative Strength Index) is 29.79 on the 14-day chart, showing oversold technical sentiment.
Is Janux Therapeutics Inc subject to short interest?
Stocks of Janux Therapeutics Inc saw a sharp steep in short interest on 2025-11-14 dropping by -1.43 million shares to 7.13 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 8.56 million shares. A decline of -20.06% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.19 of the overall float, the days-to-cover ratio (short ratio) decline to 6.19.
Which companies own the most shares of Janux Therapeutics Inc (JANX)?
In terms of Janux Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 52 in the next 12 months, up nearly 203.92% from the previous closing price of $17.11. Analysts anticipate Janux Therapeutics Inc stock to reach 72 by 2025, with the lowest price target being 38. In spite of this, 3 analysts ranked Janux Therapeutics Inc stock as Buy at the end of 2025. On September 04, 2025, Guggenheim assigned a price target of “a Buy” to the stock and initiated coverage with a $72.
